A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
Recruiting now · Phase 1
Conditions studied: Ovarian Cancer
In brief
This is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cancer (PROC) into Part 2 of the study. Part 1 of the study evaluating misetionamide in combination with gemcitabine in subjects with advanced pancreatic cancer previously treated with 5-fluorouracil-based chemotherapy completed enrolment.
Key facts
- Study ID
- NCT03854110
- Run by
- Persevere Therapeutics Inc.
- People needed
- 80
- Starts
- 2019-01-14
- Expected to finish
- 2027-09-30
- Last updated by the study team
- 2026-07-23
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Rush University Medical Center — Chicago, Illinois, United States (enrolling)
- University of Kansas Cancer Center — Fairway, Kansas, United States (enrolling)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)
- Abramson Cancer Center at the University of Pennsylvania — Phildelphia, Pennsylvania, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.